Medications that should be avoided by women who are taking tamoxifen for the prevention of breast cancer, either primary or recurrence, are listed in a review published in the Journal of Clinical Oncology.1 These new recommendations extend previous work that singled out paroxetine and fluoxetine as medications to avoid in women who are already taking […]
Major Cancer Advances in 2010
May 1, 2011 by Leave a Comment
Major advances in clinical cancer research made during the past year are highlighted in the annual report from the American Society of Clinical Oncology (ASCO).1 The report highlighted 12 studies described as ‘major advances’ (see table below). Cancer type Treatment Main results Comments Non-small cell lung cancer (NSCLC) in elderly patients Doublet chemotherapy (carboplatin and […]
Paracetamol and Pregnancy
May 1, 2011 by Leave a Comment
Paracetamol – Available evidence does not support a causal relationship with asthma in children after exposure in pregnancy or use in early infancy Paracetamol was first introduced into clinical practice in the 1950s, and has become one of the most widely used analgesic-antipyretics. Due to its safety profile, when used within therapeutic doses, it is […]
Lucentis approved for patients with visual impairment due to DME
May 1, 2011 by Leave a Comment
PDF (489KB) Novartis wish to announce that European Commission has granted a new indication for Lucentis (ranibizumab) to treat patients with visual impairment due to diabetic macular edema (DME). Macular edema is a frequent manifestation of diabetic retinopathy, which is the leading cause of blindness in the working age population. Focal/grid laser photocoagulation (referred to […]
Sutent: New indication for pancreatic NET
May 1, 2011 by Leave a Comment
Sutent Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumours PDF (185KB) Pfizer Healthcare Ireland are pleased to announce the approval of Sutent (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (NET) with disease progression in adults. Pancreatic NET is a rare cancer affecting two to four […]
Bisoprolol Fumarate Actavis
May 1, 2011 by Leave a Comment
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Prohibited in specific sports. Active ingredient: Bisoprolol hemifumarate 5mg, 10mg. Description: 5mg: Mottled pale yellow, round tablets marked BI and 5 on either side of a break-line. 10mg: Mottled beige, round tablets marked BI and 10 on either side of a break-line. Both tablets can be divided […]
Clopidogrel Niche
May 1, 2011 by Leave a Comment
Company: Niche Generics Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: 112.1mg clopidogrel besylate molar equivalent to 75mg clopidogrel base. Description: Pink, round, biconvex, film-coated tablet. Presentation: 30, €33.00. Indications: Prevention of atherothrombotic events in patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days […]
Ferinject
May 1, 2011 by Leave a Comment
Company: Vifor Pharma UK Ltd. Legal category: Prescription. Sport permitted. Active ingredient: Ferric carboxymaltose 50mg/ml. Description: Solution for injection/infusion. Presentation: 100mg/2ml-5, €158.43; 500mg/10ml-5, €778.12. Indication: Treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. Pharmacology: Ferinject solution for injection/infusion contains iron in a stable ferric state as a complex with […]
Lutinus
May 1, 2011 by Leave a Comment
Company: Ferring Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Progesterone 100mg. Description: White to off-white flat and oval vaginal tablet marked FPI on one side and 100 on the other. Presentation: 21, €24.31. Indication: Luteal support as part of an Assisted Reproductive Technology (ART) treatment program for infertile women. Pharmacology: Progesterone is […]
Resolor
May 1, 2011 by Leave a Comment
Company: Shire Pharmaceuticals Limited. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Prucalopride (as succinate) 1mg, 2mg. Description: 1mg: White to off-white, round, biconvex film-coated tablets marked PRU 1 on one side. 2mg: Pink, round, biconvex tablets marked PRU 2 on one side. Presentation: 1mg-28, €42.59; 2mg-28, €61.20. Indication: Symptomatic treatment of chronic constipation in […]
Loading ...
